VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells

Journal of Neuroimmunology

Volumn 133, Issue 1-2, 2002, Pages 81-94

  Jiang, Xiuju ^a   Jing, Huie ^a   Ganea, Doina ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Chemokines; Dendritic cells; Macrophages; Neuropeptides; Th1 Th2 chemoattractants

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MACROPHAGE DERIVED CHEMOKINE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TH2 CELL; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOKINES, CC; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; MALE; MICE; MICE, INBRED BALB C; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPLEEN; TH1 CELLS; TH2 CELLS; UP-REGULATION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0036890170     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00365-X     Document Type: Article

References (71)

1. Amishay D., Gazzinelli R.T., Karupiah G., Moench T.R., Sher A., Farber J.M. Genes for chemokines MuMig and CRG-2 are induced in protozoan and viral infections in response to IFN-γ with patterns of tissue expression that suggest nonredundant roles in vivo. J. Immunol. 157:1996;4120-4511.
2. Andrew D.P., Chang M., McNinch J., Wathen S.T., Rihanek M., Tseng J., Spielberg J.P., Elias C.G. III STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J. Immunol. 161:1998;5027-5038.
3. Arimura, A., Li, M., Somogyvari-Vigh, A., Maderdrut, J., 2001. Different concentrations of PACAP trigger different signaling pathways in neuroglia co-cultures and glia-enriched cultures: Relevance to neuroprotection by femtomolar or nanomolar concentrations of PACAP, Society for Neuroscience, 31st Annual Meeting, Abstract number 210.7.
4. Balashov K., Rottman J., Wiener H., Hancock W. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1 and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6873-6878.
5. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsani A., Sozzani S., Allavena P., Gray P.A., Mantovani A., Sinigaglis F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187:1998;129-134.
6. Bonecchi R., Sozzani S., Stine J.T., Luisi W., D'Amico G., Allavena P., Chantry P.D., Mantovani A. Divergent effects of interleukin-4 and interferon-γ on macrophage-derived chemokine production: an amplification circuit of polarized T helper 2 response. Blood. 92:1998;2668-2671.
7. Boorsma D.M., Flier J., van den Brink E.N., Sampat S., Walg H.L., Willemze R., Tensen C.P., Stoof T.J. IP-10 mRNA expression in cultured keratinocytes is suppressed by inhibition of protein kinase C and tyrosine kinase and elevation of cAMP. Cytokine. 11:1999;469-475.
8. Campbell J.J., Haraldsen G., Pan J., Rottman J., Qin S., Andrew D.P., Warnke R., Ruffing N., Kassam N., Wu L., Butcher E.C. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature. 400:1999;776-780.
9. Chang M.S., Mcninch J., Elias C., Manthey C.L., Grosshans D., Meng T., Boone T., Andrew D.P. Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifically acts on activated T lymphocytes. J. Biol. Chem. 272:1997;25229-25237.
10. Delgado M., Ganea D. VIP and PACAP enhance the in vivo generation of memory Th2 cells by inhibiting peripheral deletion of antigen-specific effectors. Arch. Physiol. Biochem. 109:2001;372-376.
11. Delgado M., Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide in vitro and in vivo. J. Immunol. 167:2001;966-975.
12. Delgado M., Ganea D. Cutting Edge: is vasoactive intestinal peptide a type 2 cytokine? J. Immunol. 166:2001;2907-2912.
13. Delgado M., Leceta J., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J. Immunol. 163:1999;3629-3635.
14. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells. J. Neuroimmunol. 96:1999;167-181.
15. Delgado M., Jonakait G.M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit chemokine production in activated microglia. Glia. 39:2002;1480161.
16. Delneste Y., Herbault N., Galea B., Magistrelli G., Bazin I., Bonnefoy J.-Y., Jeannin P. Vasoactive intestinal peptide synergizes with TNF-α in inducing human dendritic cell maturation. J. Immunol. 163:1999;3071-3075.
17. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., Luster A.D. IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168:2002;3195-3208.
18. Dunzendorfer S., Kaser A., Meierhofer C., Tilg H., Wiedermann C.J. Cutting Edge: peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells. J. Immunol. 166:2001;2167-2172.
19. Fife B.T., Kennedy K.J., Paniagua M.C., Lukacs N.W., Kunkel S.L., Luster A.D., Karpus W.J. CXCL10 (IP-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 166:2001;7124-7617.
20. Flier J., Boorsma D.M., van Beck P.J., Nieboer C., Stoof T.J., Willemze R., Tensen C.P. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL19, and CXCL11 in different types of skin inflammation. J. Pathol. 194:2001;398-405.
21. Ganea D., Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit. Rev. Oral Biol. Med. 13:2002;229-237.
22. Gattass C.R., King L.B., Luster A.D., Ashwell J.D. Constitutive expression of IP-10 in lymphoid organs and inducible expression in T cells and thymocytes. J. Exp. Med. 179:1994;1373-1378.
23. Glimcher L.H., Murphy K.M. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev. 14:2000;1693-1711.
24. Godiska R., Chantry D., Raport C.J., Sozzani S., Allavena P., Levitan D., Mantovani A., Gray P.W. Human macrophage derived chemokine (MDC) a novel chemoattractant for monocytes, monocyte derived dendritic cells, and natural killer cells. J. Exp. Med. 185:1997;1595-1604.
25. Goetzl E.J., Voice J.K., Shen S., Dorsam G., Kong Y., West K.M., Morrison C.F., Harmar A.J. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13854-13859.
26. Gonzalo J.A., Pan Y., Lloyd C.M., Jia G.Q., Yu G., Dussault B., Powers C.A., Proudfoot A.E.I., Coyle A.J., Gearing D., Gutierrez-Ramos J.C. Mouse monocyte-derived chemokine is involved in airway hyperactivity and lung inflammation. J. Immunol. 163:1999;403-411.
27. Gourlet P., Vandermeers A., Vertongen P., Ratche J., De Neef P., Cnudde J., Waelbroeck M., Robberecht P. Development of high affinity selective VIP1 receptor agonists. Peptides. 18:1997;1539-1545.
28. Gourlet P., De Neef P., Cnudde J., Waelbroeck M., Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides. 18:1997;1555-1560.
29. Grimm M.C., Doe W.F. Chemokines in inflammatory bowel disease mucosa: expression of RANTES, macrophage inflammatory protein (MIP)-1α, MIP-1β, and γ-interferon-inducible protein 10 by macrophages, lymphocytes, endothelial cells, and granulomas. Inflamm. Bowel Dis. 2:1996;88-94.
30. Gunn M.D., Tangemann K., Tam C., Cyster J.G., Rosen S.D., Williams L.T. A chemokine expressed in lymphoid high endothelial venules promotes adhesion and chemotaxis of naïve T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 95:1998;258-263.
31. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., Washek J.A. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP). Pharmacol. Rev. 50:1998;625-627.
32. Imai S.R., Nagira T.M., Tagagi S., Kakizaki M., Nishimura M., Wang J., Gray P.W., Matsushima K., Yoshie O. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int. Immunol. 11:1999;81-88.
33. Kakinuma T., Nakamura K., Wakugawa M., Mitsui H., Tada Y., Sacki H., Torii H., Komine M., Asahina A., Tamaki K. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin. Exp. Immunol. 127:2002;270-273.
34. Kalinski P., Schuitemaker J.H., Hilkens C.M., Kapsenberg M.L. Prostaglandin E2 induces the final maturation of IL-12 deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 161:1998;2804-2809.
35. Katamura K., Shintaku N., Yamauchi Y., Fukui T., Ohshima Y., Mayumi M., Furusho K. Prostaglandin E2 at priming of naïve CD4+ T cells inhibits acquisition of ability to produce IFN-γ and IL-2, but not IL-4 and IL-5 responsiveness. J. Immunol. 155:1995;4604-4612.
36. Khan I., MacLean J.A., Lee F., Casciotti L., DeHaan E., Schwartzmann J., Luster A.D. The IP-10 chemokine is critical for effector T cell trafficking and host survival in toxoplasma gondii infection. Immunity. 12:2000;483-494.
37. Kuroda E., Sugiura T., Okada K., Zeki K., Yamashita U. Prostaglandin E2 up-regulates macrophage-derived chemokine production but suppresses IFN-inducible protein-10 production by APC. J. Immunol. 166:2001;1650-1658.
38. Lloyd C.M., Delaney T., Nguyen T., Tan J., Martinez C., Coyle A.A.J., Gutierrez-Ramos J.C. CC chemokine receptor (CCR3/eotaxin) is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med. 191:2000;265-274.
39. Loetscher M., Gerber B., Loetcher P., Jones S.A., Piali L., Clark-Lewi I., Baggiolini M., Moser B. Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T cells. J. Exp. Med. 184:1996;963-969.
40. Loetscher P., Uguccioni M., Bordoli L., Baggiolini M., Moser B., Chizzolini C., Dayer J.-M. CCR5 is characteristic of Th1 lymphocytes. Nature. 391:1998;344-345.
41. Luster A.D., Ravetch J.V. Biochemical characterization of a γ interferon-inducible cytokine (IP-10). J. Exp. Med. 166:1987;1084-1097.
42. Majumder S., Zhou L.Z., Chaturvedi P., Babcock G., Aras S., Ransohoff R.M. p48/STAT-1 alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. J. Immunol. 161:1998;4736-4744.
43. Mantovani A., Gray P.A., Van Damme J., Sozzani S. Macrophage-derived chemokine. J. Leukoc. Biol. 68:2000;400-404.
44. Melter M., Exeni A., Reinders M.E., Fang J.C., McMahom G., Ganz P., Hancock W.W., Briscoe D.M. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation. 104:2001;2558-2564.
45. Miyaura H., Iwata M. Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. J. Immunol. 168:2002;1087-1094.
46. Moro O., Lerner E.A. Maxadilan, the vasodilator peptide from sand flies, is a specific pituitary adenylate cyclase-activating peptide type I receptor agonist. J. Biol. Chem. 271:1997;966.
47. Moro O., Wakita K., Ohnuma M., Denda S., Lerner E.A., Tajima M. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor specific antagonist. J. Biol. Chem. 274:1999;23103-23110.
48. Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D.E., Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 854:2000;257-262.
49. Ohmori Y., Hamilton T.A. A macrophage LPS-inducible early gene encodes the murine homologue of IP-10. Biochem. Biophys. Res. Commun. 168:1990;1261-1267.
50. Patel D.D., Zachariah J.P., Whichard L.P. CXCR3 and CCR5 ligands in rheumatoid arthritis. Clin. Immunol. 98:2001;39-45.
51. Piccinni M.-P., Guidizi M.-G., Biagiotti R., Beloni L., Giannarini L., Sampognaro S., Parronchi P., Manetti R., Annunziato F., Livi C. Progesterone favors the development of human Th cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J. Immunol. 155:1995;128-133.
52. Qin S., Rottman J.B., Myers P., Kassam N., Weinblatt M., Leotscher M., Koch A.E., Moser B., Mackay C.R. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101:1998;746-754.
53. Sallusto F., Lanzavecchia A., Mackay C.R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today. 19:1998;568-574.
54. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:1999;708-712.
55. Sallusto F., Palermo B., Lenig D., Miettinen M., Matikainen S., Julkunen I., Foster R., Burgstahler R., Lipp M., Lanzavacchi A. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur. J. Immunol. 29:1999;1617-1625.
56. Schaniel C., Pardali E., Sallusto F., Speletas M., Ruedi C., Seidl Y., Anderson J., Melchers F., Rolinck A.G., Sideras P. Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells. J. Exp. Med. 188:1998;451-463.
57. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., Qin S., Rottman J., Sellebjerk F., Strieter R.M. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103:1999;807-815.
58. Tamada K., Harada M., Abe K., Li T., Nomoto K. IL-4-producing NK1.1+ T cells are resistant to glucocorticoid-induced apoptosis: implications for the Th1/Th2 balance. J. Immunol. 161:1998;1239-1247.
59. Tang H.L., Cyster J.G. Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science. 284:1999;819-822.
60. Van den Berg A., Visser L., Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells: a possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am. J. Pathol. 154:1999;1685-1691.
61. Vanguri P., Farber J.M. Identification of CRG-2: an interferon-inducible mRNA predicted to encode a murine monokine. J. Biol. Chem. 265:1990;15049-15057.
62. Vestergaard C., Yoneyama H., Murai M., Nakamura K., Tamaki K., Terashima Y., Imai T., Yoshie O., Irimura T., Mizutani H., Matsushima K. Overproduction of Th2-type specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J. Clin. Invest. 104:1999;1097-1105.
63. Vieira P.L., Kalinski P., Wierenga E.A., Kapsenberg M.L., de Jong E.C. Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential. J. Immunol. 161:1998;5245-5251.
64. Voice J.K., Dorsam G., Lee H., Kong Y., Goetzl E.J. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 15:2001;2489-2496.
65. Vulcano M., Albanesi C., Stoppacciaro A., Bagnati R., D'Amico G., Struyt S., Transidico P., Bonecchi R., Del Prete A., Allavena P., Ruco L.P., Chiabrando C., Girolomoni G., Mantovani A., Sozzani S. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur. J. Immunol. 31:2001;812-822.
66. Wu C.Y., Wang K., McDyer J.F., Seder R.A. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J. Immunol. 161:1998;2723-2730.
67. Wu M.-T., Fang H., Hwang S.T. Cutting Edge: CCR4 mediates antigen-primed T cell binding to activated dendritic cells. J. Immunol. 167:2001;4791-4795.
68. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281:1997;629-633.
69. Xin Z., Sriram S. Vasoactive intestinal peptide inhibits IL12 and nitric oxide production in murine macrophages. J. Neuroimmunol. 89:1998;206-212.
70. Zhang Z., Kaptanoglu L., Haddad W., Ivancic D., Alnadjim Z., Hurst S., Tishler D., Luster A.D., Barrett T.A., Fryer J. Donor T cell activation initiates small bowel allograft rejection through an IFN-γ-inducible protein-10-dependent mechanism. J. Immunol. 168:2002;3205-3212.
71. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 12:2000;121-127.